Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26554912)

  • 1. Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development.
    Zhang X; He N; Gu D; Wickliffe J; Salazar J; Boldogh I; Xie J
    J Genet Genomics; 2015 Oct; 42(10):589-596. PubMed ID: 26554912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPC protects against smoking- and carcinogen-induced lung adenocarcinoma.
    Zhou H; Saliba J; Sandusky GE; Sears CR
    Carcinogenesis; 2019 May; 40(3):403-411. PubMed ID: 30624620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes.
    Melis JP; Wijnhoven SW; Beems RB; Roodbergen M; van den Berg J; Moon H; Friedberg E; van der Horst GT; Hoeijmakers JH; Vijg J; van Steeg H
    Cancer Res; 2008 Mar; 68(5):1347-53. PubMed ID: 18316597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y
    Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
    Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
    Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.
    Wu YH; Wu TC; Liao JW; Yeh KT; Chen CY; Lee H
    Cancer Res; 2010 Dec; 70(24):10422-32. PubMed ID: 21056989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice.
    Yang G; Curley D; Bosenberg MW; Tsao H
    Cancer Res; 2007 Jun; 67(12):5649-57. PubMed ID: 17575131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) Cells.
    Belloni E; Martin Padura I; Gerbino E; Orecchioni S; Fusar Imperatore F; Marighetti P; Bertalot G; Giuseppe Pelicci P; Bertolini F
    Sci Rep; 2015 Aug; 5():13047. PubMed ID: 26267334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
    Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
    J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/- mice.
    Cheo DL; Burns DK; Meira LB; Houle JF; Friedberg EC
    Cancer Res; 1999 Feb; 59(4):771-5. PubMed ID: 10029060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    Li K; Liu Y; Ding Y; Zhang Z; Feng J; Hu J; Chen J; Lian Z; Chen Y; Hu K; Chen Z; Cai Z; Liu M; Pang X
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
    Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
    Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
    Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.